1. Home
  2. LCFY vs BGLC Comparison

LCFY vs BGLC Comparison

Compare LCFY & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Locafy Limited

LCFY

Locafy Limited

HOLD

Current Price

$4.22

Market Cap

8.4M

Sector

N/A

ML Signal

HOLD

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

N/A

Current Price

$2.20

Market Cap

10.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LCFY
BGLC
Founded
2009
2017
Country
Australia
Malaysia
Employees
18
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.4M
10.1M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
LCFY
BGLC
Price
$4.22
$2.20
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.6K
5.6K
Earning Date
03-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.78
EPS
N/A
N/A
Revenue
N/A
$9,510,646.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$0.23
52 Week High
$13.98
$15.19

Technical Indicators

Market Signals
Indicator
LCFY
BGLC
Relative Strength Index (RSI) 51.44 37.92
Support Level $4.07 $2.12
Resistance Level $4.80 $2.73
Average True Range (ATR) 0.24 0.11
MACD -0.07 -0.01
Stochastic Oscillator 39.05 1.89

Price Performance

Historical Comparison
LCFY
BGLC

About LCFY Locafy Limited

Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Share on Social Networks: